Therini Plans to Move Antibody to Myelin-damaging Protein Into MS Trials multiplesclerosisnewstoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from multiplesclerosisnewstoday.com Daily Mail and Mail on Sunday newspapers.
Therini Bio, Inc., a South San Francisco, CA-based vascular biology company, raised 17m in seed extension round of financing.
The round was co-led by SV Health Investors’ Impact Medicine Fund, MRL Ventures, and Sanofi Ventures who join existing investors including the Dementia Discovery Fund and Dolby Family Ventures, as well as new investor, Foundation for a Better World. With the closing of the financing Dr. Christine Brennan, PhD from MRL Ventures and Dr. Jim Trenkle, PhD from Sanofi Ventures have joined the Therini board of directors.
The company intends to use the capital to accelerate the development of its lead program – a monoclonal antibody against fibrin – towards the clinic for patients with inflammatory conditions associated with vascular damage.
Therini Bio Secures $17 Million Investment to Advance Fibrin Therapeutic Candidates Towards the Clinic
Strengthens investor syndicate with SV s Impact Medicine Fund, MRL Ventures and Sanofi Ventures joining to accelerate development of disease-modifying drugs for dementia and other inflammatory conditions.
News provided by
Share this article
Share this article
SOUTH SAN FRANCISCO, Calif, May 10, 2021 /PRNewswire/ Therini Bio, Inc. announced it has completed an oversubscribed Seed Extension round of financing. The capital will accelerate the development of Therini s lead program – a monoclonal antibody against fibrin – towards the clinic for patients with inflammatory conditions associated with vascular damage.
Therini Bio was co-founded by Dr. Katerina Akassoglou, PhD, based upon discoveries from her laboratory at Gladstone Institutes and also UC San Francisco that a cryptic epitope on fibrin, a blood-clotting factor, drives toxic chronic inflammation in the brain and t